Literature DB >> 22761152

Health status of ayahuasca users.

Paulo Cesar Ribeiro Barbosa1, Suely Mizumoto, Michael P Bogenschutz, Rick J Strassman.   

Abstract

Ayahuasca is a psychedelic brew originally used for magico-religious purposes by Amerindian populations of the western Amazon Basin. Throughout the last four decades, the use of ayahuasca spread towards major cities in all regions of Brazil and abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine- and harmala-alkaloid-containing tea may lead to mental and physical health problems associated typically with drug abuse. To further elucidate the mental and physical health of ayahuasca users, we conducted a literature search in the international medical PubMed database. Inclusion criteria were evaluation of any related effect of ayahuasca use that occurred after the resolution of acute effects of the brew. Fifteen publications were related to emotional, cognitive, and physical health of ayahuasca users. The accumulated data suggest that ayahuasca use is safe and may even be, under certain conditions, beneficial. However, methodological bias of the reviewed studies might have contributed to the preponderance of beneficial effects and to the few adverse effects reported. The data up to now do not appear to allow for definitive conclusions to be drawn on the effects of ayahuasca use on mental and physical health, but some studies point in the direction of beneficial effects. Additional studies are suggested to provide further clarification.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761152     DOI: 10.1002/dta.1383

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  22 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 2.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

3.  Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Authors:  Marc G Blainey
Journal:  J Relig Health       Date:  2015-02

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  Determination of the Elemental Composition of Ayahuasca and Assessments Concerning Consumer Safety.

Authors:  Ivanilce Cristina Guimarães; Luís Fernando Tófoli; Alessandra Sussulini
Journal:  Biol Trace Elem Res       Date:  2020-06-05       Impact factor: 3.738

6.  Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression.

Authors:  Lindsay P Cameron; Charlie J Benson; Lee E Dunlap; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-04-24       Impact factor: 4.418

Review 7.  Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.

Authors:  Snehal R Bhatt; Maya Armstrong; Tassy Parker; Marcello Maviglia; Rebecca Kass; Lawrence Leeman; Paul Romo; Douglas Ziedonis
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

Review 8.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

9.  Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.

Authors:  Caroline Dorsen; Joseph Palamar; Michele G Shedlin
Journal:  Addict Res Theory       Date:  2018-03-30

10.  Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.

Authors:  Brian Rush; Olivia Marcus; Sara García; Anja Loizaga-Velder; Gabriel Loewinger; Ariane Spitalier; Fernando Mendive
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.